Siciliano Valentina, Sangiorgi Flavio, Del Vecchio Pierluigi, Vahedi Layla, Gross Maya Manuela, Saviano Angela, Ojetti Veronica
Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Pathogens. 2024 Feb 20;13(3):189. doi: 10.3390/pathogens13030189.
Long-acting lipoglycopeptides (LGPs), such as dalbavancin and oritavancin, are semisynthetic antibiotics known for their strong effectiveness against a wide array of Gram-positive bacteria. This includes , both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, (CoNS), streptococci, and vancomycin-sensitive . A literature search was conducted on PubMed and on ClinicalTrials.gov to identify articles published until July 2023 investigating the use of oritavancin and dalbavancin in clinical practice. The review included case reports, case series, observational studies, and clinical studies. Although more consistent data are needed, LGPs seem to be a good alternative that may provide a quicker hospital discharge and reduce long-term intravenous access and therapy. This is attributed to their unique pharmacologic and pharmacokinetic characteristics. More quality data (i.e., number of patients treated with clinical success) are needed before clinicians may use these therapies more widely.
长效脂糖肽类药物（LGPs），如达巴万星和奥利万星，是半合成抗生素，以其对多种革兰氏阳性菌具有强效而闻名。这包括甲氧西林敏感（MSSA）和甲氧西林耐药（MRSA）菌株、凝固酶阴性葡萄球菌（CoNS）、链球菌以及万古霉素敏感肠球菌。在PubMed和ClinicalTrials.gov上进行了文献检索，以识别截至2023年7月发表的关于奥利万星和达巴万星在临床实践中应用的文章。该综述包括病例报告、病例系列、观察性研究和临床研究。尽管需要更一致的数据，但LGPs似乎是一个很好的选择，可能会使患者更快出院，并减少长期静脉通路和治疗。这归因于它们独特的药理和药代动力学特性。在临床医生更广泛地使用这些疗法之前，还需要更多高质量的数据（即治疗成功的患者数量）。
